title: [Economical effectiveness of vaccination of cohort of children aged 2 years against chickenpox in the Russian Federation].
abstract: OBJECTIVE
  Perform calculation of the economical effectiveness of realization of a program of vaccination of children aged 2 years against chickenpox (CP) in the Russian Federation.
  
  
  METHODS
  Data of Federal service on customers rights protection and human well-being surveillance on evaluation of morbidity and losses caused by CP in the Russian Federation in 2008 - 2010 were used. A cohort of children (1 760 000) aged 2 years subject to vaccination against CP in 2011, evaluation of cost of 1 case of the infection, the amount of losses per vaccination of 1 child were approximately determined; analysis of prevented losses by implementation ofvaccination program by using mathematical modeling methods was performed.
  
  
  RESULTS
  Without vaccination program in the Russian Federation the cost of losses per 1 case of CP related to hospitalization and outpatient visits as well as temporary disability of one of the parent in various age groups was: for children aged 1 - 2 years--8 333 RUB (Russian rubles), 3 - 6 years--21 171 RUB, 7 - 14 years--21 295 RUB. The cost of vaccination against CP of 1 child including 2 doses of vaccines with physician examination and vaccination procedure would be 1600 RUB. In the case of realization of vaccination program against CP in 2011 of children aged 2 years its cost would be 2 488.9 million RUB. Cost prevention already exceeds the cost of vaccination in 1 age cohort of children at year 2 and in 5 years the amount of prevented losses would exceed 15 billion RUB per 1 vaccinated cohort and would continue to increase steadily.
  
  
  CONCLUSIONS
  The performed calculations show that vaccination against CP in the Russian Federation is a highly efficient investment. Self-sufficiency of a program implemented in 2011 may be obtained already at the start of year 2 after the realization and by 2016 the net economical benefit would be around 8 milliards RUB.
authors: M P
authors: MP
authors: Kostinov
authors: V V
authors: VV
authors: Zverev
mesh_terms: D000293:Adolescent; D002644:Chickenpox / Q000191:economics* / Q000453:epidemiology / Q000517:prevention & control*; D019433:Chickenpox Vaccine / Q000008:administration & dosage / Q000191:economics*; D002648:Child; D002675:Child, Preschool; D015331:Cohort Studies; D003362:Cost-Benefit Analysis / Q000706:statistics & numerical data; D005260:Female; D014645:Herpesvirus 3, Human / Q000187:drug effects / Q000502:physiology; D006760:Hospitalization; D006801:Humans; D017589:Immunization Programs / Q000191:economics*; D007223:Infant; D007902:Length of Stay; D008297:Male; D008432:Mathematical Computing; D012426:Russia / Q000453:epidemiology; D014611:Vaccination / Q000191:economics*
chemical_list: D019433:Chickenpox Vaccine